Omada Health, Inc. (OMDA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Omada Health: Business Is Scaling Very Healthily
Omada Health remains a 'Buy' as Q3 results validated strong growth, with revenue up 50% y/y to $68 million and membership reaching 831,000. OMDA's new GLP-1 prescribing capability deepens client integration, enhances ROI, and strengthens competitive positioning in a complex medication landscape. Multi-condition adoption accelerated, with ~75% of new customers using multiple programs, driving operating leverage and reducing client churn risk for OMDA.
Omada Health, Inc. (OMDA) Q3 2025 Earnings Call Transcript
Omada Health, Inc. ( OMDA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Allan Kells - Vice President of Investor Relations Sean Duffy - Co-Founder, CEO & Director Wei-Li Shao - President Steven Cook - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Craig Hettenbach - Morgan Stanley, Research Division Richard Close - Canaccord Genuity Corp., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Saket Kalia - Barclays Bank PLC, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Gene Mannheimer Presentation Operator Good day, and thank you for standing by. Welcome to the Omada Health Third Quarter 2025 Earnings Conference Call.
Compared to Estimates, Omada Health, Inc. (OMDA) Q3 Earnings: A Look at Key Metrics
The headline numbers for Omada Health, Inc. (OMDA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Omada Health: Multiple Indicators Convince Me The Growth Outlook Remains Healthy
Omada Health (OMDA) remains a buy, driven by accelerating membership growth, multi-condition adoption, and a massive underpenetrated market opportunity. OMDA's GLP-1 Care Track is a standout product, validated by clinical results and scaled distribution through major PBM partnerships, fueling enterprise customer wins. AI-driven efficiency gains are improving OMDA's operating leverage, supporting the path to gross margin expansion above 70% as the company scales.
Omada Health beats on revenue in first earnings report since IPO
Omada Health reported quarterly results for the first time since its IPO in June. Omada's revenue increased 49% in its second quarter to $61 million.
Omada Health: Long Growth Runway Ahead
I rate Omada Health a buy due to its strong clinical validation, strategic partnerships, and vast untapped market opportunity. OMDA's clinical outcomes, backed by 29 peer-reviewed studies, provide a true moat and credibility with sophisticated buyers like employers and health plans. Strategic partnerships with Cigna and CVS enable rapid scale, lower customer acquisition costs, and improve revenue visibility, accelerating OMDA's growth trajectory.
